Skip to main content
. 2020 May 28;12(6):489. doi: 10.3390/pharmaceutics12060489

Figure 1.

Figure 1

Polymeric vaccine prototypes designed for the development of an intranasal vaccine against the Mycobacterium tuberculosis fusion protein ESAT-6/CFP-10 (ECH protein). In the oily core, Imiquimod, a TLR-7 agonist, was added as adjuvant to increase the immunogenicity of the fusion protein. Ag: Antigen, CS: Chitosan, INU: Inulin, pArg: Polyarginine, TLR-7: Toll-like receptor-7.